Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Relapsed/refractory (R/R) disease is a major hurdle to long‐term survival of acute myeloid leukemia (AML) patients treated with intensive cytarabine (AraC)‐based chemotherapy. R/R AML salvage treatment with venetoclax (VEN) + azacitidine (AZA) results in overall response rates between 20% and 60%, a...

Descripción completa

Detalles Bibliográficos

Autores principales:	Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Wiley 2026-02-01
Colección:	Molecular Oncology
Materias:	acute myeloid leukemia azacitidine AZD4573 venetoclax
Acceso en línea:	https://doi.org/10.1002/1878-0261.70124
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!